2022 ASCO Educational Book发表的一篇报道“Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era”指出,当前HER2阳性转移性乳腺癌(MBC)的治疗目标是根据疾病和患者的特征量身定制治疗强度,以提高治愈率,同时...
2024年10月1日,中国医学科学院肿瘤医院徐兵河团队在Nature Medicine(IF=58.7)在线发表题为“Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial”的研究论文,该研究报告了来...
[2].Cobleigh M, Yardley DA, Brufsky AM, et al. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 Mar 1;26(5):1105-1113.[3].Rugo HS, Rumble RB, Macrae E, B...
[1]Hurvitz S.A, Modi S, Li W, et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINYBreast (DB) -01, -02, and -03. 2023 ESMO 377O. [2]G Curigliano, L...
《2022 ASCO Educational Book》发表的一篇报道“Systemic Therapy for HER2-Positive Metastatic Breast Cancer:Moving Into a New Era”指出,当前HER2阳性转移性乳腺癌(MBC)的治疗目标是根据疾病和患者的特征量身定制治疗强度,以提高治愈率,同时将过度治疗风险降到最低,这为制定HER2阳性MBC的治疗策略提示了重要方向。
(T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06...
(T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) withprior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)...
2022 ASCO Educational Book发表的一篇报道“Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era”指出,当前HER2阳性转移性乳腺癌(MBC)的治疗目标是根据疾病和患者的特征量身定制治疗强度,以提高治愈率,同时将过度治疗风险降到最低,这为制定HER2阳性MBC的治疗策略提示了重要方向。
此外,该研究也发现了分子肿瘤负荷指数(mTBI)和ctDNA清除可作为HER2-low转移性乳腺癌(metastatic breast cancer,MBC)的预后指标。医学界特整理研究精华内容,以飨读者。 图1 文章截图 研究方法与数据提取 研究人员通过回顾性分析1071例转移性乳腺癌(MBC)患者的ctDNA(图2),并基于16S rRNA基因宏条形码技术、转录组和...
1、Hurvitz,S.A.et al.A pooled analysis of trastuzumab deruxtecan(T-DXd)in patients(pts)with HER2-positive(HER2+)metastatic breast cancer(mBC)with brain metastases(BMs)from DESTINY-Breast(DB)-01,-02,and-03.Ann.Oncol.34,S335–S336(2023) ...